Outcome Measure Template Example 1

(Units=Participants; Measure Type=Number; Measure of Dispersion=NA)

ClinicalTrials.gov

Outcome Measure Type*	(Circle One) Primary Secondary Other Pre-specified Post-Hoc Safety Issue? (Circle One) Yes No	
Outcome Measure Title*	Number of Participants With Myocardial Infarction, Stroke or Death From Cardiovascular Causes	*
Outcome Measure Description	Participants were monitored for up to 2 years. This is the number of participants who have had at least one myocardial infarction or stroke, or if they died from cardiovascular causes during the time of observation.	
Outcome Measure Time Frame*	Up to 2 years	*

or to 2 years								
	Arm/Group Title*	Low-do	se Aspirin Therapy *	Beta Blocker	Therapy *		*	
Arm/Gro	oup Description ①	•	amilial history of cardiovascular 1 mg Aspirin once daily	_	familial history of sease received 100 once daily			
Number of Parti	cipants Analyzed*		1545 *	1524	*		*	
Analysis Popu	lation Description	All participants wh	no received at least one dose of treat	tment.				
, manyors i opanacion description		Measure Type* (Circle One) Number Median Least Squares Mean Geometric Mean Log Mean	Circle One) (2) Not Applicable Standard Deviation Inter-Quartile Range Full Range Standard Error 95% Confidence Interval 90% Confidence Interval	Measure Type	Dispersion/ Precision Type	Measure Type	Dispersion/ Precision Type	
Unit of Measure *	Participants *		Geometric Coefficient of Variation		_			
Category Title 4	[*]	277 *	3*	246 *	3*	*	3*	
Category Title 4	[*]	[*]	③ [*]	[*]	③ [*]	[*]	③ [*]	

* Required by ClinicalTrials.gov

- [*] Conditionally required by ClinicalTrials.gov
- 1 Arm/Group Description describes details about the interventions administered (e.g., dosage, dosage form, frequency of administration) or groups evaluated.
- (2) "Not Applicable" Dispersion/Precision Type should be used only when Measure Type is "Number". "Standard Deviation", "Standard Error", "Inter-quartile Range", and "Full Range" should NOT be used when Measure Type is "Number". "Geometric Coefficient of Variation" should be used only when Measure Type is "Geometric Mean".
- 3 No Dispersion/Precision value is needed when Dispersion/Precision Type is "Not Applicable". Numeric Lower and Upper Limits should be entered when Dispersion Precision Type is any kind of "Range" or "Interval". A single number should be entered for all other Dispersion/Precision Types.
- (4) [Optional] Add as many Categories as needed. When more than one Category is entered, a Category Title and Outcome Measure Data are required for each row. Outcome Measure data is required in at least one row. Category Titles are only required if more than one row.

Outcome Measure Template Example 2

(NCT00444457 Units=Percentage of Participants; Measure Type=Number: Measure of Dispersion=95% CD

ClinicalTrials.gov

			Type Ital	moor, mount or 215	persion /t	5 / C C 1 /				_
Outcome Measure Type*	(Circl	e One) Primary	Secondary	Other Pre-sp	ecified	Post-Hoc	Safety Issue?	(Circle On	ne) Yes	No
Outcome Measure Title*	Perce	ntage of Participant	ts Achieving Pr	edefined Antibody	Level ≥0	0.1 International	Units Per Millilite	r (IU/mL)	for Tetan	nus Toxoid*
Outcome Measure Description		ercentage of participants achieving predefined antibody threshold \geq 0.1 IU/ mL along with the corresponding 95% CI for concomitant ntigen tetanus toxoid are presented. Exact 2-sided CI was based on the observed proportion of participants.								
Outcome Measure Time Frame*	1 moi	onth after the infant series (7 months of age)								
Arm/Group Title*			41αFv1	*		34αF	'v1	*		*

	Arm/Group Title*		41αFv1 *	* 34αFv1			*	
Arm/Gro	oup Description ①	of 41α-Strain Fluvo	ed 1 single 0.5 milliliter (mL) dose occoccal 1 conjugate vaccine and 6 months of age (infant series) ge (toddler dose)	Participants received of 34α-Strain Fluvor (34αFv1) at 2, 4, and and 12 months of ag				
Number of Part	icipants Analyzed*	184 *			*			
Analysis Popu	ulation Description	Immunogenicity po	pulation: N=number of participants ponent.	analyzed with a deter	minate post-third dose IgG antiboo	ly concentrat	tion to the	
Percentage of		Measure Type* Circle One Number Mean Median Least Squares Mean Geometric Mean Log Mean	Circle One) ② Not Applicable Standard Deviation Inter-Quartile Range Full Range Standard Error 95% Confidence Interval 90% Confidence Interval	Measure Type Dispersion/ Precision Type		Measure Type	Dispersion/ Precision Type	
Unit of Measure *	Participants		Geometric Coefficient of Variation					
Category Title 4	[*]	98.4 *	95.3 to 99.7 3*	98.5 *	95.6 to 99.7 3*	*	3 *	
Category Title 4	[*]	[*]	③ [*]	[*]	③ [*]	[*]	③ [*]	

Required by ClinicalTrials.gov

- [*] Conditionally required by ClinicalTrials.gov
- Arm/Group Description describes details about the interventions administered (e.g., dosage, dosage form, frequency of administration) or groups evaluated.

"Not Applicable" Dispersion/Precision Type should be used only when Measure Type is "Number". "Standard Deviation", "Standard Error", "Inter-quartile Range", and "Full Range" should NOT be used when Measure Type is "Number". "Geometric Coefficient of Variation" should be used only when Measure Type is "Geometric Mean".

- (3) No Dispersion/Precision value is needed when Dispersion/Precision Type is "Not Applicable". Numeric Lower and Upper Limits should be entered when Dispersion Precision Type is any kind of "Range" or "Interval". A single number should be entered for all other Dispersion/Precision Types.
- (4) [Optional] Add as many Categories as needed. When more than one Category is entered, a Category Title and Outcome Measure Data are required for each row. Outcome Measure data is required in at least one row. Category Titles are only required if more than one row.

Outcome Measure Template Example 3

(Change Outcome Measure with more than 2 Arms, Including mean and standard deviation)

ClinicalTrials.gov

Outcome Measure Type*	(Circle One) Primary Secondary	Other Pre-specified	Post-Hoc	Safety Issue?	(Circle One)	Yes	No
Outcome Measure Title*	Change in Low-density Lipoprotein (LDL) Cholesterol					*
Outcome Measure Description							
Outcome Measure Time Frame*	Baseline, 3 months						*

	Arm/Group Title*	Statin Drug 5 mg		*	Statin Drug 80 mg			Omega-3 Supplement *			
Arm/Group Description ①		All participants received 5 mg Statin Drug once daily.			All participants received 80 mg Statin Drug once daily.			All participants received Omega -3 Supplement containing 900 mg EPA and 5 g DHA once daily.			
Number of Participants Analyzed*		28		*	32 *		3	1	*		
Analysis Popu	lation Description	All participants fo	or whom LDL measurements were	re re	corded at Baseline	and 3 month	ıs.				
		Measure Type* (Circle One) Number Mean Median Least Squares Mean Geometric Mean Log Mean	Circle One) (2) Not Applicable Standard Deviation Inter-Quartile Range Full Range Standard Error 95% Confidence Interval 90% Confidence Interval	· *	Measure Type	Dispersion T	-	Measure Type	Dispersion T	-	
Unit of Measure *	mg/dL		Geometric Coefficient of Variation	on							
Category Title 4	[*] -55.4 *	5.2	3*	-78.1 *	4.8	3 *	-32.3 *	10.6	3 *	
Category Title 4		*] [*.	3	[*]	[*]		3 [*]	[*.]	③ [*]	

* Required by ClinicalTrials.gov

- [*] Conditionally required by ClinicalTrials.gov
- 1 Arm/Group Description describes details about the interventions administered (e.g., dosage, dosage form, frequency of administration) or groups evaluated.
- (2) "Not Applicable" Dispersion/Precision Type should be used only when Measure Type is "Number". "Standard Deviation", "Standard Error", "Inter-quartile Range", and "Full Range" should NOT be used when Measure Type is "Number". "Geometric Coefficient of Variation" should be used only when Measure Type is "Geometric Mean".
- 3 No Dispersion/Precision value is needed when Dispersion/Precision Type is "Not Applicable". Numeric Lower and Upper Limits should be entered when Dispersion Precision Type is any kind of "Range" or "Interval". A single number should be entered for all other Dispersion/Precision Types.
- (4) [Optional] Add as many Categories as needed. When more than one Category is entered, a Category Title and Outcome Measure Data are required for each row. Outcome Measure data is required in at least one row. Category Titles are only required if more than one row.

More details available in the "Basic Results" Data Flement Definitions. Sept 11, 2012

ClinicalTrials.gov Outcome Measure Template Example 4 (to illustrate appropriate use of NA feature) (Circle One) Primary Safety Issue? Outcome Measure Type* Other Pre-specified Yes Secondary Post-Hoc (Circle One) Outcome Measure Title* Median Time to Response of Target Lesions using RECIST Criteria Median Time from 1st dose of treatment to Complete or Partial Response. Target lesions are scanned via MRI to determine dimensions. Response Evaluation Criteria In Solid Tumors (RECIST) Complete Response is defined to be a disappearance of all target lesion(s). RECIST **Outcome Measure Description** Partial Response is defined to be at least a 30% decrease in the sum of the target lesion longest diameters (LDs). Outcome Measure Time Frame* Up to 24 months 37.5 mg INX123 75.0 mg INX123 **Arm/Group Title*** INX123 75.0 mg once daily on a continuous daily INX123 37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long dosing schedule. Study medication continued as long **Arm/Group Description (1)** as patient was obtaining clinical benefit, or until as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up significant toxicity, or withdrawal of consent, for up to 24 months. to 24 months. **Number of Participants Analyzed*** 29 25 All participants with Baseline and at least one post-baseline target lesion measurement. **Analysis Population Description Dispersion/Precision Type *** Measure Type* (Circle One) (Circle One) (2) Dispersion/ Number Not Applicable Dispersion/ Measure Standard Deviation **Precision Measure Type Precision Type** Type Median Inter-Quartile Range **Type Full Range** Geometric Mean Standard Error 95% Confidence Interval Log Mean Unit of Measure * Months Geometric Coefficient of Variation 9 to NA 4 to NA

Required by ClinicalTrials.gov

Category Title 4

Category Title 4

- [*] Conditionally required by ClinicalTrials.gov

Not enough participants

calculate upper 95% CI

achieved response to

10

[*]

[*]

- Arm/Group Description describes details about the interventions administered (e.g., dosage, dosage form, frequency of administration) or groups evaluated.
- "Not Applicable" Dispersion/Precision Type should be used only when Measure Type is "Number". "Standard Deviation", "Standard Error", "Inter-quartile Range", and "Full
- Range" should NOT be used when Measure Type is "Number". "Geometric Coefficient of Variation" should be used only when Measure Type is "Geometric Mean".
- (3) No Dispersion/Precision value is needed when Dispersion/Precision Type is "Not Applicable". Numeric Lower and Upper Limits should be entered when Dispersion Precision Type is any kind of "Range" or "Interval". A single number should be entered for all other Dispersion/Precision Types.

3*

(3) [*

15

[*]

Not enough participants

calculate upper 95% CI

achieved response to

(3)

(3) [*

3*

3 [*]

[*]

[Optional] Add as many Categories as needed. When more than one Category is entered, a Category Title and Outcome Measure Data are required for each row. Outcome Measure data is required in at least one row. Category Titles are only required if more than one row.